Accelerator Platforms

Start your development project with our accelerator platform services, designed to speed up phase I clinical trial readiness and derisk development approaches.

Get ready with our Developability Assessment and Preformulation Screening platform services for monoclonal antibodies (mAbs). Drawing from our extensive scientific expertise, we have designed these service platforms to help our clients determine the ideal strategy right from the start while keeping an eye on potential stage-related risks. While developed as platform services for mAbs, our early-stage services might also be applicable to other therapeutic proteins or peptides on request.

Developability Assessment

Reduce time to market and costs while mitigating risk for your mAb program with our streamlined and innovative approach. Select the most promising antibody candidates with the most favorable biophysical properties as a foundation for successful drug product development, accelerating time to market.

The Developability Assessment service package includes:

- High throughput, low sample consumption methods for candidate screening
- Supported by in silico analysis using machine learning tools
- Assessment in one matrix
- Benchmarking to commercial antibody drug products
- In-depth characterization with dedicated methods to determine self-interactions and predict risk at high concentration
- Supported by in silico analysis with machine learning and molecular dynamics simulation
- Assessment in two matrices
- Benchmarking to commercial antibody drug products
- Application of our full advanced method set for predicting stability and the influence of the formulation
- Supported by in silico analysis with machine learning and molecular dynamics simulation
- Assessment in four matrices
- Benchmarking to commercial antibody drug products

Preformulation Screening

Go from molecule to formulation within six weeks with our preformulation screening service. Systematically screen a vast formulation space, including only excipients accepted for parenteral application, and comprehensively generate holistic drug product development data, including accelerated stability and forced degradation readouts. This approach allows for the careful selection of lead formulations for subsequent stability studies and further preclinical drug product development for your mAb program.

- Preparation of 80 formulation variants
- Conformational stability
- Colloidal stability
- Chemical stability
- Protein–protein interaction
- Basic characterization
- Standardized data analysis and visualization
- Focused design of experiments evaluation
- Result interpretation from Coriolis experts
- Heat maps for formulation selection

We’ve worked with over 930 modalities, and the number is growing by the day.

Your Drug Product

Coriolis Pharma’s deep expertise across many biologic modalities, combined with input from world-leading external advisors, offers the knowledge and experience needed to solve even the most complex formulation and drug development challenges. We’ve worked with more than 930 compounds, including drug substances like live virus vaccines, viral vectors or cell therapies that require biosafety level 2.

Antibody or Related Product

Peptide

Therapeutic Protein

Gene & Cell Therapy

Viral Vector

Nucleic Acid

Vaccine

Nanoparticulate Delivery Systems

Your Phase

Our expert team has the knowledge and experience to guide your program from discovery to preclinical drug development, through clinical phases and to the market.

Preclinical

Early Phase

Late Phase & Commercialization

Commercial Services

Coriolis Effect

See how our expertise and comprehensive services accelerate biologics development from preclinical to the market.